Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04814940
Other study ID # 000395
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date September 1, 2022
Est. completion date September 1, 2023

Study information

Verified date June 2022
Source Ferring Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this retrospective observational study is to describe the treatment patterns with MENOPUR and to understand the clinical impact for patients that underwent infertility treatment under real-world setting. The primary objective is to describe the treatment patterns for the general population and for selected patient profiles.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 1, 2023
Est. primary completion date September 1, 2023
Accepts healthy volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Consecutive adult females who underwent ART treatment with MENOPUR for ovarian stimulation in 2018 Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
MENOPUR Cohort
Non-interventional All directions for medication usage were solely at the discretion of the investigator in accordance with their usual routine clinical practice and are assumed to be consistent with the national prescribing information of the medicinal product in the country in which the study take place.

Locations

Country Name City State
Israel Assuta Medical Center Ltd Tel-aviv

Sponsors (1)

Lead Sponsor Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment duration with MENOPUR (complete patient population and subgroups analysis) Duration of treatment (in days) with MENOPUR for complete patient population and subgroup of patients will be reported. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Day of MENOPUR stimulation start (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At the day of the first MENOPUR injection during the ovarian stimulation treatment (during 20 days) in 2018
Primary Day of MENOPUR stimulation end (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At the day of the last MENOPUR injection during the ovarian stimulation treatment (during 20 days) in 2018
Primary Starting dose of MENOPUR prescribed in IU (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. From day 1 up to day 20 of MENOPUR stimulation during 2018
Primary Dose Adjustment of MENOPUR in IU (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. From day 1 up to day 20 of MENOPUR stimulation during 2018
Primary Total dose of MENOPUR (complete patient population and subgroup analysis) Defined as total dose of MENOPUR used during the treatment duration. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. From day 1 up to day 20 of MENOPUR stimulation during 2018
Primary Addition of gonadotropin (s) in case of mixed ovarian stimulation treatment (complete patient population and subgroup analysis) In case of mixed treatments with gonadotropin (s) at the discretion of the investigator, addition of gonadotropin (s) will be reported. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to the end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Mixed treatment duration with added gonadotropin (s) (complete patient population and subgroup analysis) In case of mixed treatments with gonadotropin (s), total duration with added gonadotropin (s) will be reported. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Day of treatment with additional gonadotropin (s) start (complete patient population and subgroups analysis) The time point of the start of the stimulation is decided at the discretion of the investigator. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At the day of the first additional gonadotropin (s) injection during the ovarian stimulation treatment (during 20 days) in 2018
Primary Day of treatment with additional gonadotropin (s) end (complete patient population and subgroups analysis) The time point of the end of the stimulation is decided at the discretion of the investigator. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At the day of the last additional gonadotropin (s) injection during the ovarian stimulation treatment (during 20 days) in 2018
Primary Starting dose of added gonadotropin (s) (complete patient population and subgroup analysis) In case of mixed treatments with gonadotropin (s), starting dose of added gonadotropin (s) will be reported. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At the day of the first added gonadotropin (s) injection during the ovarian stimulation treatment (during 20 days) in 2018
Primary Dose adjustment of added gonadotropin (s) (complete patient population and subgroup analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Total dose of additional gonadotropin (s) (complete patient population and subgroup analysis) Defined as total dose of additional gonadotropin (s) used during the treatment duration. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Treatment prescription day with additional gonadotropin (s) up to the end of stimulation treatment (up to 20 days) during 2018
Primary Type of gonadotropin releasing hormone (GnRH) used for Lutenizing Hormone(LH) surge suppression (complete patient population and subgroups analysis) Defined as a choice between GnRH agonist and GnRH antagonist. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At consultation visit where the LH surge suppression protocol is decided during 2018
Primary Day of LH surge suppression protocol start (complete patient population and subgroups analysis) The time point of the start of LH surge suppression is decided at the discretion of the investigator. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At the day of the first GnRH administration during the ovarian stimulation treatment (during 20 days) in 2018
Primary Day of LH surge suppression protocol end (complete patient population and subgroups analysis) The time point of the end of LH surge suppression is decided at the discretion of the investigator. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At the day of the last GnRH administration during the ovarian stimulation treatment (during 20 days) in 2018
Primary Total number of follicles >=12 millimeter (mm) at the end of stimulation (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Circulating levels of progesterone (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Circulating levels of estrogen (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Type of drug used for the triggering of follicle maturation (complete patient population and subgroups analysis) Decided at the discretion of the investigator. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At consultation visit where the triggering of follicle maturation is decided during 2018
Primary Date of administration of human chorionic gonadotropin (hCG) and/or GnRH for follicle maturation (complete patient population and subgroups analysis) Date when the investigator decides to trigger the final follicle maturation. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At the day of administration during 2018
Primary Endometrium description: endometrial thickness (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Endometrium description: triple line visible (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Endometrium description: poorly defined central line (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Up to end of the ovarian stimulation treatment (up to 20 days) during 2018
Primary Type of drug used for Luteal phase support (complete patient population and subgroups analysis) Decided at the discretion of the investigator between progesterone, oestrogen and hCG. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. From ovum pick-up (OPU) day up to the end of luteal phase support during 2018
Secondary Number of oocytes retrieved (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Treatment prescription day with MENOPUR (during 2018) up to the delivery
Secondary Number of fresh or frozen embryo transfer (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Treatment prescription day with MENOPUR (during 2018) up to the delivery
Secondary Quality and number of embryo(s) transferred in fresh and frozen cycles (complete patient population and subgroups analysis) Total number of embryo(s) and total number of good-quality embryo (s) transferred will be reported. Embryo quality is defined at the discretion of the investigator according to their routine practice. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Treatment prescription day with MENOPUR (during 2018) up to the delivery
Secondary Pregnancy rate (complete patient population and subgroups analysis) Defined as positive pregnancy 2 weeks after embryo transfer. Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. 2 weeks after embryo transfer
Secondary Live birth rate (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At delivery
Secondary Live birth parameter: gestation duration (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At delivery
Secondary Live birth parameter: gender (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At delivery
Secondary Live birth parameter: weight (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. At delivery
Secondary Percentage of pregnancy loss (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Treatment prescription day with MENOPUR (during 2018) up to the delivery
Secondary Number of patients with cycle cancellation before and after the ovum pick-up (OPU) (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. From treatment prescription day with MENOPUR (during 2018) up to the OPU day during 2018 and from the OPU day during 2018 up to the delivery
Secondary Percentage of preventive measures for early ovarian hyper-stimulation syndrome (OHSS) (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Treatment prescription day with MENOPUR (during 2018) up to the delivery
Secondary Rate of OHSS occurence (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Treatment prescription day with MENOPUR (during 2018) up to the delivery
Secondary Rate of early and late OHSS (complete patient population and subgroups analysis) Subgroup analysis refers to subgroups of patients stratified by patient baseline characteristics. Treatment prescription day with MENOPUR (during 2018) up to the delivery
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05358483 - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer